CytoGenix, Inc. Announces the Appointment of Mr. Kevin Cassidy to Its Board of Directors

CytoGenix, Inc. Announces the Appointment of Mr. Kevin Cassidy to Its Board of Directors

NEW YORK--(BUSINESS WIRE)--Oct 14, 2010 - CYTOGENIX, INC (Pink Sheets:CYGX) announced today that it has appointed Mr. Kevin Cassidy to its Board of Directors.

Kevin Cassidy currently serves in New York as the Managing Member and Founder of Logic International Consulting Group www.logic-Int.com. Mr. Cassidy also served as the Chief Operating Officer for Bank Julius Baer (BJB), www.juliusbaer.com based in Zurich. He was a member of the BJB Trading Management Committee and responsible for organizing and directing the re-branding of the BJB global trading platform, including both new product and business development. In addition, Mr. Cassidy developed the global FX Option Trading Business and Operating Support Paradigm for the Bank.

Prior to BJB, Mr. Cassidy was Managing Director of UBS, www.ubs.com where he was the Global Head of Fixed Income Derivatives Support. Kevin also served as the Global Head of the Bank's Derivatives Infrastructure, including operations, finance, systems IT and Legal, etc. While at UBS, Mr. Cassidy was also President of UBS Securities Swaps, Inc., the bank's US based derivatives platform and business center, responsible for the North Americas Fixed Income Derivatives Business. Further, he was responsible for the Global infrastructure and business platform, including Systems, IT, Finance & Accounting, including operations and legal support. Earlier in his career, Mr. Cassidy was Managing Director of Bear Sterns, where he was credited with the development of multiple new products, including, Currency Exchange Warrants (CEW's) and Remarketed Preferred, and was also responsible for the new product planning and development group.

Mr. Cassidy began his career at Merrill Lynch where he rose to the position of Senior Section Manager in charge of New Product Planning & Development. In this position, he was credited with the development of (i) the Re-marketed Preferred Product and Trading Platform, and (ii) the development of the Short Term Put Securities Product and Global Trading Platform.

Lex Cowsert, CEO of CYGX stated, "Kevin Cassidy has an incredible reputation as a businessman and banker. He has repeatedly demonstrated his abilities throughout his career and has succeeded at every level. Kevin will bring all of those attributes to CytoGenix which will help CytoGenix meet its goals of bringing profitability to the company."

Dr. Cy Stein, Chairman of the Board of Directors of CYGX stated, "I am very excited that Kevin has joined the Board of Directors, from the onset of developing our new strategic plans, we knew that we were going to need a member of the board that can help direct our global initiatives. The caliber of Kevin's accomplishments certainly meets this criteria and will only help CytoGenix implement our plans more effectively to create certain shareholder value."

CytoGenix, Inc.

CytoGenix is a Nevada corporation traded under the symbol: CYGX.PK. CytoGenix is a biotechnology company developing biotechnology derived products for vaccines and therapeutic applications for human, agricultural and veterinary markets. As such, CytoGenix has access to a broad range of biological expertise that can be leveraged to identify, evaluate, develop and commercialize biologically based technologies for energy production.

Safe Harbor Statement

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Important factors, including general economic conditions, spending levels and other factors could cause actual results to differ materially from the Company's expectations.

 

 

Contact: CytoGenix, Inc.
Lex M. Cowsert, 830-632-5944
[email protected]

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.